Cargando…

Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2)

Although insulin resistance consistently occurs with type 1 diabetes, its predominant driver is uncertain. We therefore determined the relative contributions of hyperglycemia and iatrogenic hyperinsulinemia to insulin resistance using hyperinsulinemic-euglycemic clamps in three participant groups (n...

Descripción completa

Detalles Bibliográficos
Autores principales: Gregory, Justin M., Smith, T. Jordan, Slaughter, James C., Mason, Holly R., Hughey, Curtis C., Smith, Marta S., Kandasamy, Balamurugan, Greeley, Siri Atma W., Philipson, Louis H., Naylor, Rochelle N., Letourneau, Lisa R., Abumrad, Naji N., Cherrington, Alan D., Moore, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692813/
https://www.ncbi.nlm.nih.gov/pubmed/31092478
http://dx.doi.org/10.2337/db19-0324
_version_ 1783443609718095872
author Gregory, Justin M.
Smith, T. Jordan
Slaughter, James C.
Mason, Holly R.
Hughey, Curtis C.
Smith, Marta S.
Kandasamy, Balamurugan
Greeley, Siri Atma W.
Philipson, Louis H.
Naylor, Rochelle N.
Letourneau, Lisa R.
Abumrad, Naji N.
Cherrington, Alan D.
Moore, Daniel J.
author_facet Gregory, Justin M.
Smith, T. Jordan
Slaughter, James C.
Mason, Holly R.
Hughey, Curtis C.
Smith, Marta S.
Kandasamy, Balamurugan
Greeley, Siri Atma W.
Philipson, Louis H.
Naylor, Rochelle N.
Letourneau, Lisa R.
Abumrad, Naji N.
Cherrington, Alan D.
Moore, Daniel J.
author_sort Gregory, Justin M.
collection PubMed
description Although insulin resistance consistently occurs with type 1 diabetes, its predominant driver is uncertain. We therefore determined the relative contributions of hyperglycemia and iatrogenic hyperinsulinemia to insulin resistance using hyperinsulinemic-euglycemic clamps in three participant groups (n = 10/group) with differing insulinemia and glycemia: healthy control subjects (euinsulinemia and euglycemia), glucokinase–maturity-onset diabetes of the young (GCK-MODY; euinsulinemia and hyperglycemia), and type 1 diabetes (hyperinsulinemia and hyperglycemia matching GCK-MODY). We assessed the contribution of hyperglycemia by comparing insulin sensitivity in control and GCK-MODY and the contribution of hyperinsulinemia by comparing GCK-MODY and type 1 diabetes. Hemoglobin A(1c) was normal in control subjects and similarly elevated for type 1 diabetes and GCK-MODY. Basal insulin levels in control subjects and GCK-MODY were nearly equal but were 2.5-fold higher in type 1 diabetes. Low-dose insulin infusion suppressed endogenous glucose production similarly in all groups and suppressed nonesterified fatty acids similarly between control subjects and GCK-MODY, but to a lesser extent for type 1 diabetes. High-dose insulin infusion stimulated glucose disposal similarly in control subjects and GCK-MODY but was 29% and 22% less effective in type 1 diabetes, respectively. Multivariable linear regression showed that insulinemia—but not glycemia—was significantly associated with muscle insulin sensitivity. These data suggest that iatrogenic hyperinsulinemia predominates in driving insulin resistance in type 1 diabetes.
format Online
Article
Text
id pubmed-6692813
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-66928132020-08-01 Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2) Gregory, Justin M. Smith, T. Jordan Slaughter, James C. Mason, Holly R. Hughey, Curtis C. Smith, Marta S. Kandasamy, Balamurugan Greeley, Siri Atma W. Philipson, Louis H. Naylor, Rochelle N. Letourneau, Lisa R. Abumrad, Naji N. Cherrington, Alan D. Moore, Daniel J. Diabetes Metabolism Although insulin resistance consistently occurs with type 1 diabetes, its predominant driver is uncertain. We therefore determined the relative contributions of hyperglycemia and iatrogenic hyperinsulinemia to insulin resistance using hyperinsulinemic-euglycemic clamps in three participant groups (n = 10/group) with differing insulinemia and glycemia: healthy control subjects (euinsulinemia and euglycemia), glucokinase–maturity-onset diabetes of the young (GCK-MODY; euinsulinemia and hyperglycemia), and type 1 diabetes (hyperinsulinemia and hyperglycemia matching GCK-MODY). We assessed the contribution of hyperglycemia by comparing insulin sensitivity in control and GCK-MODY and the contribution of hyperinsulinemia by comparing GCK-MODY and type 1 diabetes. Hemoglobin A(1c) was normal in control subjects and similarly elevated for type 1 diabetes and GCK-MODY. Basal insulin levels in control subjects and GCK-MODY were nearly equal but were 2.5-fold higher in type 1 diabetes. Low-dose insulin infusion suppressed endogenous glucose production similarly in all groups and suppressed nonesterified fatty acids similarly between control subjects and GCK-MODY, but to a lesser extent for type 1 diabetes. High-dose insulin infusion stimulated glucose disposal similarly in control subjects and GCK-MODY but was 29% and 22% less effective in type 1 diabetes, respectively. Multivariable linear regression showed that insulinemia—but not glycemia—was significantly associated with muscle insulin sensitivity. These data suggest that iatrogenic hyperinsulinemia predominates in driving insulin resistance in type 1 diabetes. American Diabetes Association 2019-08 2019-05-15 /pmc/articles/PMC6692813/ /pubmed/31092478 http://dx.doi.org/10.2337/db19-0324 Text en © 2019 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
spellingShingle Metabolism
Gregory, Justin M.
Smith, T. Jordan
Slaughter, James C.
Mason, Holly R.
Hughey, Curtis C.
Smith, Marta S.
Kandasamy, Balamurugan
Greeley, Siri Atma W.
Philipson, Louis H.
Naylor, Rochelle N.
Letourneau, Lisa R.
Abumrad, Naji N.
Cherrington, Alan D.
Moore, Daniel J.
Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2)
title Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2)
title_full Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2)
title_fullStr Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2)
title_full_unstemmed Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2)
title_short Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2)
title_sort iatrogenic hyperinsulinemia, not hyperglycemia, drives insulin resistance in type 1 diabetes as revealed by comparison with gck-mody (mody2)
topic Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692813/
https://www.ncbi.nlm.nih.gov/pubmed/31092478
http://dx.doi.org/10.2337/db19-0324
work_keys_str_mv AT gregoryjustinm iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2
AT smithtjordan iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2
AT slaughterjamesc iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2
AT masonhollyr iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2
AT hugheycurtisc iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2
AT smithmartas iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2
AT kandasamybalamurugan iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2
AT greeleysiriatmaw iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2
AT philipsonlouish iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2
AT naylorrochellen iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2
AT letourneaulisar iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2
AT abumradnajin iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2
AT cherringtonaland iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2
AT mooredanielj iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2